期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 61, 期 10, 页码 850-862出版社
ELSEVIER
DOI: 10.1016/j.addr.2009.04.018
关键词
RNA interference; Cancer; siRNA delivery; Lipoplex; Polyplex; Targeted delivery
资金
- Ministry of Education, Science and Technology [F104AA010002-08A0101-00210, F104AA010003-08A0101-00310]
- Ministry of Health and Welfare [A04-0041-B21004-07M4-00040B]
- National Research Laboratory
- Korea Health Promotion Institute [A040041] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [2008-56366] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
With increasing knowledge on the molecular mechanisms of endogenous RNA interference, small interfering RNAs (siRNAs) have been emerging as innovative nucleic acid medicines for treatment of incurable diseases such as cancers. Although several siRNA candidates for the treatment of ocular and respiratory diseases are undergoing clinical trials, there are challenges inherent in the further development of siRNAs for anti-cancer therapeutics, because systemic administration will be required in most cases. In addition to nonspecific off-target and immune stimulation problems, appropriate delivery remains a major hurdle. The technologies developed for delivery of nucleic acid medicines such as plasmid DNA and antisense oligonucleotides have paved the way to rapid progress for in vivo delivery of siRNAs. Here, we review various in vivo delivery strategies including chemical modification, conjugation, lipid-based techniques, polymer-based nanosystems, and physical methods. Moreover, the current progress in siRNA delivery systems for gynecologic, liver, lung, and prostate cancers is discussed. (C) 2009 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据